CAJ | 학술논문

Delta样分子4(DUA)在恶性肿瘤高表达可导致血管发生,对恶性肿瘤的生长发育具有促进作用,其下调却可起到抗血管发生的作用,表现肿瘤组织中形成大量无功能的血管,阻碍肿瘤的生长,这一特点使其用于对血管内皮生长因子(VEGF)抑制剂耐受肿瘤的治疗.近来,DLL4单克隆抗体药物进入了临床研究,对耐受VEGF阻滞剂的肿瘤有较好的疗效,但也导致一些不良反应,如能有效预防DLL4的不良作用,将会对恶性肿瘤有更高的临床应用价值.
Delta양분자4(DUA)재악성종류고표체가도치혈관발생,대악성종류적생장발육구유촉진작용,기하조각가기도항혈관발생적작용,표현종류조직중형성대량무공능적혈관,조애종류적생장,저일특점사기용우대혈관내피생장인자(VEGF)억제제내수종류적치료.근래,DLL4단극륭항체약물진입료림상연구,대내수VEGF조체제적종류유교호적료효,단야도치일사불량반응,여능유효예방DLL4적불량작용,장회대악성종류유경고적림상응용개치.
Up-regulation of DLL4 contributes to the angiogenesis in malignant tumors, and thus promote tumor growth. While down-regulation of DLL4 would cause antiangiogenesis and restrain tumor growth through forming a large number of no-function blood vessels. Thus it can be used in anti-VEGF tolerant tumors. Recently, DLL4 monoclonal antibody agents have entered clinic studies, and has achieved good curative effect in anti-VEGF tolerant tumors, but there are also some side effects. DLL4 would bring higher clinic value for cancer therapy if the side effects can be prevented effectively.